Literature DB >> 32012274

Exploratory analysis of anti-insulin antibodies in diabetic dogs receiving recombinant human insulin.

M Lester1, A L O'Kell2.   

Abstract

OBJECTIVES: To quantify anti-insulin antibodies in diabetic dogs treated with recombinant human insulin and to determine if insulin dosage or duration of treatment differed between anti-insulin antibody-positive and -negative diabetic dogs.
MATERIALS AND METHODS: Descriptive preliminary study using serum from 24 client-owned diabetic dogs treated for a minimum of 2 weeks with recombinant human insulin, and 24 client-owned healthy control dogs without diabetes. Sera were analysed by radioimmunoassay for anti-insulin antibodies. The proportion of antibody positive dogs was compared between groups by Fisher's exact test.
RESULTS: Four diabetic (16.6%) and no control dogs were anti-insulin antibody positive. CLINICAL SIGNIFICANCE: These results indicate that treatment with recombinant human insulin may induce anti-insulin antibodies in dogs, although this finding needs to be re-investigated in a larger study to investigate the impact of anti-insulin antibodies on glycaemic control.
© 2020 British Small Animal Veterinary Association.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32012274     DOI: 10.1111/jsap.13102

Source DB:  PubMed          Journal:  J Small Anim Pract        ISSN: 0022-4510            Impact factor:   1.522


  1 in total

1.  Ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in dogs.

Authors:  Sean E Hulsebosch; Jully Pires; Michael J Bannasch; Thomas Lancaster; Andrea Delpero; Ramya Ragupathy; Sylaja Murikipudi; Todd Zion; Chen Gilor
Journal:  J Vet Intern Med       Date:  2022-05-27       Impact factor: 3.175

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.